Connor Clark & Lunn Investment Management Ltd. boosted its stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) by 62.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 359,197 shares of the company's stock after buying an additional 138,510 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.37% of Poseida Therapeutics worth $1,027,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new stake in shares of Poseida Therapeutics during the first quarter worth about $110,000. Vanguard Group Inc. raised its position in shares of Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company's stock worth $10,760,000 after acquiring an additional 473,746 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Poseida Therapeutics by 280.3% in the 1st quarter. Lazard Asset Management LLC now owns 28,679 shares of the company's stock valued at $91,000 after purchasing an additional 21,138 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in Poseida Therapeutics by 177.3% during the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company's stock worth $201,000 after buying an additional 40,245 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in shares of Poseida Therapeutics during the first quarter worth approximately $33,000. 46.87% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the sale, the chairman now directly owns 651,291 shares in the company, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.90% of the stock is currently owned by insiders.
Poseida Therapeutics Stock Performance
Shares of Poseida Therapeutics stock traded down $0.05 on Thursday, reaching $9.33. 3,346,633 shares of the stock were exchanged, compared to its average volume of 699,993. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $909.35 million, a PE ratio of -14.81 and a beta of 0.54. Poseida Therapeutics, Inc. has a 1-year low of $1.87 and a 1-year high of $9.42. The business has a fifty day moving average price of $3.14 and a two-hundred day moving average price of $3.05.
Analysts Set New Price Targets
A number of analysts recently weighed in on PSTX shares. HC Wainwright reiterated a "neutral" rating and set a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. Cantor Fitzgerald lowered Poseida Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday. BTIG Research reaffirmed a "neutral" rating on shares of Poseida Therapeutics in a research note on Tuesday. Finally, William Blair reiterated a "market perform" rating on shares of Poseida Therapeutics in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $9.50.
Read Our Latest Research Report on PSTX
Poseida Therapeutics Company Profile
(
Free Report)
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Featured Stories
Before you consider Poseida Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Poseida Therapeutics wasn't on the list.
While Poseida Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
